Barnes & Noble Education (BNED) vs. Bio-Path (BPTH) Financial Analysis

Barnes & Noble Education (NYSE: BNED) and Bio-Path (NASDAQ:BPTH) are both small-cap consumer discretionary companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Insider and Institutional Ownership

How to Become a New Pot Stock Millionaire

69.2% of Barnes & Noble Education shares are held by institutional investors. 3.5% of Barnes & Noble Education shares are held by insiders. Comparatively, 11.2% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Barnes & Noble Education has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of 2.73, indicating that its stock price is 173% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Barnes & Noble Education and Bio-Path, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Barnes & Noble Education 0 0 2 0 3.00
Bio-Path 0 0 1 0 3.00

Barnes & Noble Education currently has a consensus price target of $12.00, suggesting a potential upside of 70.70%. Bio-Path has a consensus price target of $15.00, suggesting a potential upside of 644.42%. Given Bio-Path’s higher possible upside, analysts plainly believe Bio-Path is more favorable than Barnes & Noble Education.


This table compares Barnes & Noble Education and Bio-Path’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Barnes & Noble Education -12.31% -41.88% -18.50%
Bio-Path N/A -72.98% -59.29%

Earnings and Valuation

This table compares Barnes & Noble Education and Bio-Path’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Barnes & Noble Education $1.87 billion 0.18 $5.36 million $0.11 63.91
Bio-Path $40,000.00 571.25 -$6.75 million ($0.80) -2.52

Barnes & Noble Education has higher revenue and earnings than Bio-Path. Bio-Path is trading at a lower price-to-earnings ratio than Barnes & Noble Education, indicating that it is currently the more affordable of the two stocks.


Barnes & Noble Education beats Bio-Path on 8 of the 13 factors compared between the two stocks.

About Barnes & Noble Education

Barnes & Noble Education, Inc. operates bookstores for college and university campuses, and private/parochial K-12 schools in the United States. The company operates in two segments, Barnes & Noble College and MBS Textbook Exchange. The Barnes & Noble College segment sells and rents course material; offers a suite of digital content, software, and services through its LoudCloud platform, as well as etextbooks; and sells general merchandise, including collegiate and athletic apparel, other custom-branded school spirit products, technology, supplies, and convenience items. It also operates 83 customized cafés and 17 stand-alone convenience stores; and a media channel for brands targeting the college demographic. As of April 29, 2017, this segment operated 769 physical bookstores; and 61 True Spirit sites. The MBS Textbook Exchange segment is involved in the operation of virtual bookstores, which offer course materials, including new and used print and digital textbooks; and textbook distribution activities, as well as sale of inventory management, hardware, and point-of-sale software. It also provides digital suite of course materials and platforms; new, used, and digital textbooks online; and digital content. This segment operates 712 virtual bookstores, including 454 virtual stores at K-12 schools; and Barnes & Noble Education, Inc. was founded in 1873 and is based in Basking Ridge, New Jersey.

About Bio-Path

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Receive News & Ratings for Barnes & Noble Education Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barnes & Noble Education and related companies with's FREE daily email newsletter.

Leave a Reply